Janssen-Cilag receives EC approval for Trevicta for maintenance treatment of schizophrenia

Johnson & Johnson subsidiary Janssen-Cilag International has been granted approval by the European Commission (EC) for the use of Trevicta (paliperidone palmitate a three-monthly injection) for the maintenance treatment of schizophrenia in adult pati…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news